<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03721302</url>
  </required_header>
  <id_info>
    <org_study_id>NeoOBS 001</org_study_id>
    <nct_id>NCT03721302</nct_id>
  </id_info>
  <brief_title>NeoAMR Observational Study in Neonatal Sepsis</brief_title>
  <official_title>A Prospective, Multinational, Observational, Cohort Study Sepsis in Hospitalised Neonates in Areas With High Endemic Levels of Antimicrobial Resistance.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Drugs for Neglected Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St George's, University of London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PENTA Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universiteit Antwerpen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Drugs for Neglected Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multinational, multicentre, observational cohort study of neonatal sepsis in
      partner institutions. The cohort study will be designed to evaluate health care utilization
      and current clinical practice and to assess risk factors for and outcomes of babies with
      neonatal sepsis (culture-negative and culture-positive).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. NeoSEPSIS: Consecutive hospitalized babies with neonatal sepsis will be recruited and
           followed up until discharge from hospital or death (for a maximum of 28 days). A minimal
           neonatal sepsis dataset will determine (i) clinical presentations, associated features
           and risk factors (for example prematurity, SGA (small for gestational age)), (ii) rates
           of culture-positivity among babies with sepsis, (iii) current empirical treatment
           approaches (antimicrobials selected, dose, etc) (iv) outcomes of sepsis, including
           death, need for intensive care interventions and recurrence of sepsis during the
           follow-up period. Microbiological samples will be taken from sterile sites, blood and
           CSF, as clinically indicated and will be processed locally.

        2. NeoBSI: Consecutive babies with positive blood/CSF cultures and sepsis will be
           recruited. Patient inclusion will be based on identification of relevant specified
           bacteria from blood / CSF cultures. In addition to the data collected for NeoSEPSIS,
           information will be collected on the isolates and their antimicrobial susceptibility
           patterns.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 16, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality Rate</measure>
    <time_frame>28 days</time_frame>
    <description>To estimate mortality rates in hospitalised infants less than 60 days of age who are being treated for significant sepsis (where significant is defined as presenting with 2 or more of the signs /symptoms listed in the inclusion criteria).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the microbiological epidemiology, including antimicrobial susceptibility and resistance mechanisms, in infants with positive blood and/or cerebrospinal fluid culture</measure>
    <time_frame>28 days</time_frame>
    <description>The incidence of culture positive and culture negative sepsis (both bloodstream and CSF isolates)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">3600</enrollment>
  <condition>Neonatal SEPSIS</condition>
  <arm_group>
    <arm_group_label>Main Study Clinical Sepsis</arm_group_label>
    <description>Clinical and Antimicrobial Assessments</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microbiology Sub study</arm_group_label>
    <description>Clinical and Antimicrobial Assessments</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Main study clinical sepsis</intervention_name>
    <description>No intervention-Observational study</description>
    <arm_group_label>Main Study Clinical Sepsis</arm_group_label>
    <arm_group_label>Microbiology Sub study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Microbiology sub study</intervention_name>
    <description>Analysis of Bacterial isolates</description>
    <arm_group_label>Microbiology Sub study</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Microbiological isolates
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized Babies with significant sepsis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In-patient in the hospital (NNU (Neonatal unit) or paediatric ward) of one of the
             partner institutions

               -  Age &lt;60 days of age

               -  Clinical suspicion of a new episode of sepsis (as defined below)** together with
                  planned treatment with IV antibiotics OR new episode of confirmed bacterial
                  meningitis^ OR new episode of infection in which a Carbapenem-resistant organism
                  (CRO) is isolated from blood culture OR new episode of infection in which a
                  candida species is isolated from blood culture

               -  Informed consent from parent / guardian

               -  Willingness to provide location information and to be contacted at 28 days from
                  start of antibiotic treatment

        Exclusion Criteria:

          -  â€¢ Previously enrolled in this study, unless readmitted and re-started on antibiotics
             before the 28 day follow-up limit is reached

               -  Enrollment in any interventional trial

               -  A serious, non-infective co-morbidity (other than prematurity), anticipated to
                  cause death within 72 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>60 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mike Sharland</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. George's Hospital, University of London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nathalie Khavessian</last_name>
    <phone>0041225551912</phone>
    <email>nkhavessian@dndi.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tygerberg Hospital</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Dramowski</last_name>
      <phone>0027 21 9389224</phone>
      <email>dramowski@sun.ac.za</email>
    </contact>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <reference>
    <citation>Folgori L, Ellis SJ, Bielicki JA, Heath PT, Sharland M, Balasegaram M. Tackling antimicrobial resistance in neonatal sepsis. Lancet Glob Health. 2017 Nov;5(11):e1066-e1068. doi: 10.1016/S2214-109X(17)30362-5.</citation>
    <PMID>29025624</PMID>
  </reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 4, 2018</study_first_submitted>
  <study_first_submitted_qc>October 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2018</study_first_posted>
  <last_update_submitted>October 29, 2018</last_update_submitted>
  <last_update_submitted_qc>October 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Neonatal Sepsis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

